Dementia
Conditions
Interventions
Sponsors
National Institute of Radiological Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Normal controls - Subjects who have the ability to provide informed consent - Memory Complaints None - Memory Function Logical Memory II subscale (delayed Paragraph Recall) from the Wechsler Memory Scaled - Revised (the maximum score is 25): a) more than or equal to 9 for 16 or more years of education b) more than or equal to 5 for 10-15 years of education c) more than or equal to 3 for 0-9 years of education - MMSE 24-30 - CDR 0 Memory Box score must be 0 - General Cognition Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living - Hachinski Modified Hachinski score of less than or equal to 4 Mild cognitive impairment - Memory Complaints Memory complaint by subject or study partner that is verified by a study partner - Memory Function Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale - Revised: a) less than or equal to 8 for 16 or more years of education b) less than or equal to 4 for 10-15 years of education c) less than or equal to 2 for 0-9 years of education - MMSE 24-30 - CDR 0.5 Memory Box score must be at least 0.5 - General Cognition General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit - Hachinski Modified Hachinski score of less than or equal to 4 Alzheimer's disease - Memory Complaints Memory complaint by subject or study partner that is verified by a study partner - Memory Function (Same as mild cognitive impairment) - MMSE 12-26 - CDR 0.5-2 - General Cognition NINCDS/ADRDA criteria for probable AD - Hachinski Modified Hachinski score of less than or equal to 4
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients - Other psychiatric disorders including drug dependence - Brain organic diseases including cerebrovascular diseases, Parkinson's disease and other related disorders - Serious medical illness - Subjects who are judged as not suitable for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution volume and binding potential measured by positron emission tomography with [C-11]AZD2184 - Comparison between quantification methods - Comparison between patients and age- and gender-matched normal controls | — |
Countries
Japan
Outcome results
None listed